Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ADPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.19B
- EPS (TTM)
- -$0.41
- Dividend yield
- None
- 52-week range
- 12.00 – 30.74
- Day range
- 25.87 – 26.93
- Volume / Avg
- 2.12M / 2.39M
- Beta
- —
- Shares outstanding
- 159.60M
- Next earnings
- Nov 4, 2026
52-week range
ADPT stock today
Shares of Adaptive Biotechnologies (ADPT) finished lower on Oct 7 at $26.28, a drop of 2.30% or $0.62 per share, versus the S&P 500's 0.22% decline. Shares are 14.5% below their 52-week high of $30.74, set on Oct 6, 2026 and 119.0% above the 52-week low of $12.00, in the middle of the past year's range. ADPT is up 61.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 83.1%.
Adaptive Biotechnologies has posted a net loss over the last twelve months (EPS of -$0.41), so its P/E ratio is not meaningful. Adaptive Biotechnologies's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Adaptive Biotechnologies
Company profileAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Chad M. Robins M.B.A.
- Headquarters
- Seattle, WA
- Employees
- 624
- IPO year
- 2019
- Website
- adaptivebiotech.com
Financial highlights
Full financialsIn fiscal 2025, Adaptive Biotechnologies generated $277.0 million in revenue, up 54.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Adaptive Biotechnologies reported a net loss of $59.5 million, compared with a loss of $159.5 million a year earlier. Gross margin was 74.2% (up from 59.7%) and operating margin -20.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M |
| Growth | +54.77% | +5.10% | -8.11% | +20.06% | +56.88% |
| Net income | $-59.50M | $-159.49M | $-225.25M | $-200.19M | $-207.28M |
| EPS (diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$28.31+7.72%
- Strong buy 2
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.10
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.25 vs —
ADPT news
All ADPT newsAdaptive Biotechnologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs ADPT |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs ADPT |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs ADPT |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs ADPT |
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs ADPT |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs ADPT |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs ADPT |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs ADPT |
Indexes, lists and sector
Adaptive Biotechnologies stock FAQ
What is Adaptive Biotechnologies's stock price today?
ADPT last traded at $26.28 as of Oct 7, 4:00 PM EDT, down 2.30% on the day. Prices are delayed at least 15 minutes.
When is Adaptive Biotechnologies's next earnings date?
Adaptive Biotechnologies is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.10.
Who is Adaptive Biotechnologies's CEO?
Mr. Chad M. Robins M.B.A. is the chief executive officer of Adaptive Biotechnologies Corporation, which has about 624 employees.
What is the ADPT 52-week high?
The 52-week high for ADPT is $30.74 and the 52-week low is $12.00. The stock is currently 14.5% below its high.